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1. SUMMARY 
Obesity has become a priority health issue for many governments and organisations such 
as the WHO, it has gained the status of epidemic and according to the past years trends, the 
forecasts are not hopeful. The research for anti-obesity drugs has grown in the past years as 
the percentage of obese people grows globally. A relatively new anti-cancer drug (C75) was 
tested as anti-cancer drug to rodents, and it was observed that the specimens were showing an 
anorexigenic behaviour. The molecule was interacting in the hypothalamus reducing the food 
intake. Since this side effect was discovered many have been the attempts to find derivatives 
and analogues of C75 focusing on its food intake modulator basal. 
In this project, we have focused on the synthesis of C75 analogue called (±)-UB-207 that 
was first reported in 2012. The novelty of the present work consists in modifying the initial 
synthetic route in order to simplify the obtainment of the pure derivative. 
Keywords: anti-obesity, food intake, hypothalamus, C75.  
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2. RESUMEN 
La obesidad se ha convertido en un asunto sanitario de alta prioridad en los objetivos de 
gobiernos y organizaciones tales como la OMS, ha ganado el estatus de epidemia y las 
previsiones no son alentadoras. La investigación para hallar fármacos anti-obesidad ha crecido 
en los últimos años a medida que el porcentaje de obesos aumenta globalmente. Un fármaco 
(C75) relativamente reciente fue probado como antitumoral en roedores, y se observó que los 
especímenes mostraban un comportamiento anorexigénico. La molécula estaba interactuando 
en el hipotálamo reduciendo la ingesta de alimentos. Desde que este efecto secundario fue 
descubierto muchos han sido los intentos para hallar derivados y análogos del C75 
enfocándose en su vertiente como regulador de la ingesta. 
En este trabajo nos hemos centrado en la síntesis de un análogo del C75 llamado (±)-UB-
207, cuya primera síntesis fue descrita en 2012. La novedad de este trabajo consiste en la 
modificación de la ruta sintética con el objetivo de facilitar su obtención. 
Palabras clave: anti-obesidad, ingesta de alimento, hipotálamo, C75. 
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3. INTRODUCTION 
3.1. OBESITY AS A PUBLIC HEALTH CHALLENGE 
Obesity is one of the greatest public health challenges of the 21st century. Defined as 
abnormal or excessive fat accumulation that presents a risk to health, obesity is globally 
considered an epidemic disease by the World Health Organisation (WHO). According to the 
WHO obesity causes at least 2.8 million deaths each year either by direct consequence or by 
any of its non-communicable diseases (NCDs), including cardiovascular diseases, diabetes and 
certain types of cancer. [1] In addition, obesity and overweight lead to adverse metabolic effects 
on cholesterol levels, blood pressure and insulin resistance. As our body mass index (BMI) 
increases so do the risks of coronary disease, ischemic stroke and type 2 diabetes. A high BMI 
increases risk of cancer of the breast, colon, prostate, endometrium, kidney and gall bladder. As 
a result, obesity also strongly affects economic and social development. Adult obesity and 
overweight are responsible for up to 6 % of health care expenditure in the European Region; 
moreover, they impose indirect costs (due to the loss of lives, productivity and related income) 
that are at least two times higher. [2] Once considered a problem only in high income countries, 
overweight and obesity are now dramatically on the rise in low- and middle-income countries, 
particularly in urban settings. 
In 2016, 39 % of both adult men and women were overweight (BMI) ≥ 25 kg/m2) and 11 % 
of men and 15 % of women were obese (BMI ≥30 kg/m2). Thus, nearly 2 billion adults 
worldwide were overweight and, of these, more than 500 million were obese. Both overweight 
and obesity have shown a marked increase over the past 4 decades. Obesity rates have risen 
from around 3 % in men and 6 % in women in 1975 wherein overweight has risen over this 
same period from 20 % in men and 23 % in women. Its prevalence has tripled in many countries 
of the WHO European Region since the 1980s, and the numbers of those affected continue to 
rise at an alarming rate (Figure 1). [3]  
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Figure 1. Graphic showing the percentage of prevalence of obesity among adults over the years in Spain, Europe and Worldwide.  [2] 
One may be lead to the conclusion that after all these years of increasing and desolating 
tendencies, governments and societies would have already found the way to solve this public 
health issue. However, it is not just that we have not achieve a solution, but the future seems to 
follow the exact same tendency, as the prevalence of overweight and obesity among children 
and adolescents (aged 5-19) has risen dramatically from 4 % in 1975 to just over 18 % in 2016 
(18 % of girls and 19 % of boys were overweight). While just under 1 % of children and 
adolescents were obese in 1975, nearly 7 % were obese by 2016. [1]  
Fortunately, in the past years, a drug intended to be used as a treatment for certain types of 
cancer has shown a side effect that can lead us to a potential application against obesity as it 
lowers the food intake. [4] 
3.2. STARVING CANCER 
C75 was one of the molecules synthesized in 1997 by Kuhadja et al. [5]. It was designed as 
an inhibitor of the fatty acid synthase (FAS) enzyme which is responsible for the biosynthesis of 
palmitate from malonyl-CoA and acetyl-CoA. [6] 
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Since tumour cells present a typical phenotype of abnormally elevated FAS activity, 
targeting the enzyme has been aim of many studies. It has been proved that C75 is capable of 
inhibit the FAS by binding to the enzyme and stopping its activity, reducing the synthesis of 
lipids and leading to an eventual increase of cell apoptosis. [8] 
The drug was tested on cell lines and animal models, in these last, the specimens 
presented a reduction on their food intake which meant that the molecule was interfering 
somewhere else apart of the FAS. [5] 
3.3. STARVING THE BRAIN 
The hypothalamus is responsible for the regulation of thirst, blood pressure, body 
temperature and appetite. Thus, hypothalamus plays a key role on the energy homeostasis of 
our body and the control of food intake. Following a complex pathway, neurons sense the fatty 
acid (FA) concentration in blood to start a chain neuron response. Depending on the 
concentration of FA that response will cause hyperphagia (when FA concentration is low) or 
hypophagia (when FA concentration is high). [7] Particularly, it has been proved that the levels of 
malonyl-CoA and long chain fatty acids-CoA (LCFA-CoA) were higher before reduced food 
intake behaviour. [7] Hence, C75 may be interfering the FA metabolism. 
3.4. FATTY ACID OXIDATION (FAO) 
Fatty acid oxidation (FAO) is one of the most important cellular energy sources. It is carried 
out in the mitochondria of the eukaryotes to generate acetyl-CoA which participates in a large 
list of biochemical processes, from the citric acid cycle to the melatonin synthesis. FAO 
machinery involves numerous steps and processes, but probably the first step, which is the 
entrance of the FA to the mitochondria, might be the key one due to our capability to modulate 
it. 
The membrane transport of the FA to the mitochondria matrix will be different depending of 
the size of its chain: 
a) A short chain FA will react with ATP thanks to acyl-CoA synthase giving its CoA ester, 
now the fatty acyl-CoA is small enough to diffuse from the outer mitochondrial 
membrane all the way to the inner mitochondrial membrane and finally arrive to the 
mitochondria matrix. 
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b) When a LCFA arrives to the outer membrane it is first converted to its CoA ester, but 
the mitochondrial membrane is not permeable to LCFA (over 12C) so the acyl-CoA 
will be converted to acylcarnitine derivative by the enzyme carnitine 
palmitoyltransferase 1 (CPT1). Acylcarnitine is now a substrate for the shuttle-
transporter carnitine acylcarnitine translocase (CACT), which allows the transit of 
acylcarnitine from cytosol to the mitochondria matrix. Once inside, the enzyme 
carnitine palmitoyltransferase 2 (CPT2) reconverts the acylcarnitine to acyl-CoA which 
is now ready to enter the FAO cycle (Figure 2). [4] 
 
Figure 2. Long chain fatty acids are first converted to their CoA esters thanks to acetyl-CoA synthase enzyme. Enzyme CPT1 
transports the LCFA-CoA to the intermembrane space by making the LCFA-carnitine. The transport is continued by CACT which takes 
the molecule to the inner membrane, there the CPT2 reconverts the LCFA-carnitine to LCFA-CoA which is now ready to start the β-
oxidation process. 
Since the mechanism of the LCFA transport into the mitochondria and the function of CPT1 
was elucidated in 1983 by Fritz and Yue [11] and McGarry and Foster [12] many have been the 
attempts to design small molecules to modulate the function of the enzyme. Most of the 
modulators consist of inhibitors of the CPT1, wherein many of these molecules could be divided 
between oxirane carboxylic acids and derivatives and/or analogues of carnitine. Our research 
focuses on synthesizing derivatives of C75, placing more emphasis on its anti-obesity basal. 
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3.5. C75 
C75 or trans-4-methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid is a trisubstituted 
α-methylene-γ-butyrolactone similar to the natural products family of paraconic acids. As 
explained above, C75 presents bioactivity since it affects both the biosynthesis of lipids (by 
inhibiting FAS) and the FAO (inhibiting CPT1). [4] 
Previous work in the group carried out by K. Makowski showed that each enantiomer was 
responsible for a particular biological activity, being the (–)-C75 the inhibitor of the FAS and the 
(+)-C75 the CPT1 inhibitor (Figure 3). [10] 
Furthermore, it was proved that the (+)-C75 was not directly inhibiting CPT1 but its ester 
with coenzyme A which was really exhibiting the anorexigenic properties. Nonetheless, the 
adduct (+)-C75-CoA is naturally formed in vivo and it does not require the acetyl-CoA enzyme to 
be formed. [4] 
 
Figure 3. Scheme showing the double edged-sword behaviour of the C75 enantiomers.  
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These are some examples of C75 analogues synthesized in the research group in previous 
years. 
 
Figure 4. Analogues of C75. 
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4. OBJECTIVES 
On the basis of these precedents, in this project we focused on keep developing and 
studying new C75 analogues.  
Two main goals were pursued, one of them being the synthesis of analogue (±)-UB-207 
following a modified route that could give us access to new regioisomer intermediaries that were 
easier to separate, thus, eventually leading us to improve the synthesis of the target molecule. 
On the other hand, by making early modifications on the synthetic route we wanted not just 
exploring a new way to synthesize the same analogue but to get to new derivatives of C75 for 
further studies. 
The specific objectives of this work were: 
i) Synthesis of (±)-UB-207 1 
ii) Synthesis of 3-methyl-6a-octyldihydrofuro[2,3-b]furan-2,5(3H,4H)-dione (2) 
iii) Synthesis of 3-methylene-6a-octyldihydrofuro[2,3-b]furan-2,5(3H,4H)-dione (3) 
iv) Synthesis of (S)-2-((2S,3R)-4-methylene-2-octyl-5-oxotetrahydrofuran-3-yl)propanoic 
acid (4) 
v) Synthesis of 2-((2S,3R)-2-octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-3-
yl)acetic acid (5) 
 
Figure 5. Objective molecules. 
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5. RESULTS AND DISCUSSION 
This section has been divided in two parts. One will explain the synthesis of the enzymatic 
inhibitor and the other will explain the different attempts to achieve new intermediates. 
5.1. SYNTHESIS OF (±)-UB-207 
5.1.1. Background  
The target molecule was first synthetized by K. Makowski in 2012 during his PhD thesis. [10] 
In his thesis, Makowski followed the procedure reported by Parker [13] in 1973 to form the γ-
butyrolactone. 
 
Scheme 1. a) N2-atm,185 ºC, DMAP (cat), then 7 in three portions (1 h between each portion), 5 h at 185 ºC, 77%; b) KOH, 85 ºC, then 
NaBH4 at 85 ºC for 5 h, r.t. and HCl to pH 1, 97%; c) N2-atm, LiHMDS, -78 ºC then 10 dissolved in THF (anh), 1 h; r.t. and 
CF3CO2CH2CF3 for 1 h; d) work-up and K2CO3, 18-crown-6, paraformaldehyde, 80 ºC, 2 h, 100 ºC, 4 h, work-up.  
In this case, the α-methylenation was carried out following the procedure reported by Colby 
[14] in 2011 which was first tested by Rosa Diego in a similar molecular model during her MSc 
final project, leading Oscar Benito to finally apply the method in the UB-207 synthesis during his 
MSc final project. 
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5.1.2. Synthesis of 6a-octyldihydrofuro[2,3-b]furan-2,5(3H,4H)-dione 
The bis-lactone preparation consists of an acylative decarboxylation of tricarballyllic acid by 
an acid anhydride. Although the reaction was studied by Lawson [15] we followed the procedure 
described by Parker. [13] On average the yield obtained by the group until now was 44 % but 
thanks to the addition of DMAP, which acts as a catalyst, the yield has been almost doubled to 
reach 77 %, the increasing of the first step yield means an important improvement to the 
synthesis. As reported before in the group, no further purification was needed for the product. 
The purity of bis-lactone 8 was checked by 1H-NMR and it could be directly used in next steps 
of the synthesis. 
 
Scheme 2. Proposed mechanism for the bis-lactone formation. 
5.1.3. Ketone reduction and lactonization 
Next step of the synthesis is also based on the procedure reported by Parker [13] which 
consists in the opening of the bis-lactone 8 in basic media, followed by the reduction of the 
ketone and finally a lactonization in acidic media. Only one diastereoisomer was formed 
thermodynamically as is less strained than the other one. The yield obtained (97 %) was similar 
as reported by the literature and the reaction crude needed no purification for further reactions, 
as shown in the 1H-NMR spectra. 
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Scheme 3. Proposed mechanism for the reduction and further lactonization of the bis-lactone. 
5.1.4. α-Methylenation 
It is required to introduce an exocyclic methylene in the α position of the carbonyl group to 
finally obtain UB-207. In order to do that, we followed the procedure reported by Colby [14] which 
uses the easy elimination of a trifluoroacetate group during the formation of the olefin.  
5.1.4.1. Trifluoroacetylation 
The first step of the methylenation consists in the incorporation of a trifluoroacetyl group, it 
was carried out following the Danheiser’s protocol using LiHMDS and CF3CO2CH2CF3. [16] 
 
Scheme 4. Proposed mechanism for the trifluoroacetylation. 
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5.1.4.2. Trifluoroacetyl group elimination 
Next, the release of trifluoroacetyl was carried out using a milder base such as K2CO3 
which promoted an easier formaldehyde addition due to the enhanced acidity of the enolic 
proton. 
 
Scheme 5. System equilibrium favouring the enol tautomer. 
 
Scheme 6. Proposed mechanism for the trifluoroacetylate release and olefin formation. 
The main issue with this method is the formation of an undesired regioisomer due to the 
carbonyl group of the carboxylic acid. Furthermore, it was studied before by O. Benito that 
modifying the experimental conditions could hardly enhance the original ratio of the 
desired/undesired product of 70:30. 
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Scheme 7. Appearance of regioisomers after the trifluoacetylation. 
Since the separation of the two carboxylic acids by column chromatography was not possible, 
two different derivatives where synthesized in order to enhance the purification of the desire 
product. 
5.1.5. Synthesis of the methyl esters 
First, we were decide to mask the acid group as it was probably the reason of the poor 
separation between regioisomers. A simple esterification was done using TMSCl and MeOH [17] 
giving the methyl ester and not needing further purification. 
However, the separation was not fully completed. Besides, the deprotection was not 
complete and the lactone seemed to be opening under the conditions used, generating more 
isomers and making it harder to separate. Probably an interesting test to run should be the 
esterification using a different kind of ester which could be released under orthogonal conditions 
with the lactone. 
 
Scheme 8. Proposed mechanism for the methyl ester formation. 
20 Galindo Muñoz, Alex 
 
5.1.6. Synthesis of the selenide ethers 
Alternatively, we synthesized selenide ethers to protect the olefins. Makowski had tried this 
method mainly to protect the double bond from reactions conditions and to profit its stability over 
the olefin for a better storage. [10] Using a diphenyl selenide and a hydrogen source the reaction 
was conducted to a complete conversion. Then, after oxidation with H2O2 and thanks to the low 
stability of the selenoxide the elimination can be easily achieved if there is a hydrogen in β-
position, [10] thus, recovering the olefin. It is worth saying that the ether oxidation occurred in 
mere contact with the atmosphere. 
The regioisomers could be separated by column chromatography (80:20 CH2Cl2:hexanes). 
 
Scheme 9. Proposed mechanism for the selenide ether formation. 
 
Scheme 10. Proposed mechanism for the selenide ether oxidation. 
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5.2. SYNTHESIS OF 3-METHYL-6A-OCTYLDIHYDROFURO[2,3-B]FURAN-2,5(3H,4H)-
DIONE 
An interesting derivative to synthesize previous to the reduction and lactonization of the bis-
lactone was the α-methylated product. In case the methylation was achieved a hypothetic α-
methylenation directly on the bis-lactone could be tested, thus, avoiding the appearance of 
regioisomers, reducing the efforts on separating the desire product. 
 
Scheme 11. a) A mix of 8 and a base, under N2 atm, - 78 ºC for 2h; b) Heat to r.t., add MeI, stir for 2h. 
A series of experiments were run modulating the conditions to test the reactivity of the bis-
lactone in front of a enolization. 
Base Mole equivalents Temperature [ºC] Time [h] 
LiHMDS 1 - 78 2 
LiHMDS 2 - 78 2 
LDA 1 - 78 2 
LDA 2 - 78 2 
tBuLi 1 - 78 2 
tBuLi 2 - 78 2 
tBuLi 2 - 78 24 
NaH 1 60 2 
NaH 1 60 15 
Table 1. The mole equivalents are referring to the mole number in respect of the bis-lactone, the quantity of bis-lactone in each case 
could be different. Time shown in the table is the reaction time between the base and the bis-lactone, in all the cases the reaction time 
with de MeI was 2 hours. All the reactions were carried out using a CO2-acetone bath and were isolated from the atmosphere cannulating 
the solutions. 
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Unluckily, no methylation attempt conducted to the desired product. Due to the lack of 
literature exploring enolization on similar models to our bis-lactone no further test was run. With 
the few data collected one may be led to the conclusion that somehow the bis-lactone system 
was favouring a nucleophilic attack from the base to the carbonyl instead of the enolization. 
Simulating the potential surface of the molecule could be interesting to check if there’s really an 
increase of the electrophilic behaviour in comparison to the γ-butyrolactone. 
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6. EXPERIMENTAL SECTION 
6.1. MATERIALS AND METHODS 
All reactions were done under atmospheric pressure and the non-aqueous ones also under 
a nitrogen atmosphere, with magnetic stirring. 
6.1.1. Reagents and solvents 
All reagents were commercially available and used without further purification.  
Tetrahydrofuran (THF) was distilled from sodium and benzophenone immediately prior to use 
while other solvents used were dried following the conventional techniques. 
6.1.2. Nuclear magnetic resonance spectroscopy (NMR) 
The NMR spectra were recorded at 25 ºC on a Varian Mercury 400 MHz, using CDCl3 as 
solvent containing tetramethyilsilane (TMS) as internal standard. Coupling constants (J) are 
given in Hz, chemical shifts in parts per million (ppm) and the signals multiplicities are indicated 
with the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of 
doublets), ddd (doublet of doublets of doublets), m (multiplet). 
6.1.3. Chromatographic techniques 
Analytical TLC was performed on aluminium plates pre-coated with silica gel, 0.20 nm thick 
(F254 Merck), solvents used are indicated in each case. TLC were visualised directly under UV 
lamp (254 nm and 365 nm) or dipping the TLC plate into stain solutions of phosphomolybdic 
acid or potassium permanganate. 
Column chromatography was carried out using a middle pressure technique (flash), with 
silica gel Chromatogel 60 Å (35-70 µm), and the solvents used are indicated in each case. 
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6.2. SYNTHETIC PROCEDURES 
6.2.1. Synthesis of 6a-octyldihydrofuro[2,3-b]furan-2,5(3H,4H)-dione (8) 
In a round bottom flask, nonanoic anhydride (10 mL, 0.028 mol) with DMAP (0.12 g, 0.98 
mmol) were heated to 185 ºC, then tricarballylic acid (1.83 g, 0.010 mol) was added in three 
portions at 1 hour intervals. The mixture was heated at 185 ºC for further 5 hours. After cooling 
down to room temperature, 30 mL of hexane at 0 ºC were added to the brown solid obtained 
and the resulting suspension was filtered and the solid was washed with hexanes at 0 ºC. Then 
the solvent was removed to afford 2.05 g (77 % yield) of 8 as a colourless solid. 
Product 8 
Colourless solid. Rf = 0.43 (hexanes/EtOAc, 6:4). m.p. = 201–
202 ºC 1H NMR (CDCl3, 400 MHz): δ 3.16 – 3.06  (m, 1H, H-3), 
2.99 (dd, J = 18.3, 9.7 Hz, 1H, H-2a), 2.54 (dd, J = 18.4, 4.3 Hz, 
1H, H-2b), 2.05 – 1.91 (m, 1H, CH2-1’), 1.52 – 1.41 (m, 2H, CH2-
2’), 1.40 – 1.27 (m, 10H, CH2-3’ CH2-4’ CH2-5’ CH2-6’ CH2-7’), 0.90 
(t, J = 13.6 Hz, 3H, CH3-8’). 13C NMR (CD3OD, 101 MHz): δ = 
175.5 (C, C-1), 116.8 (C, C-4), 38.5 (CH, C-3), 38.1 (CH2, C-1’), 
36.2 (CH2, C-2), 33.0 (CH2, C-7’), 30.5 (CH2,C-3’), 30.4 (CH2, C-
4’), 30.3 (CH2, C-5’), 23.9 (CH2, C-2’), 23.7 (CH2, C-6’), 14.4 (CH3, 
C-8’) 
6.2.2. Synthesis of (±)-2-((2S,3R)-2-octyl-5-oxotetrahydrofuran-3-yl)acetic acid (10) 
The dilactone 8 (0.97 g, 3.8 mmol) was dissolved in 15 mL of a 1M KOH solution and then 
heated to 65 ºC. Once the dilactone is totally dissolved, sodium borohydride (0.37 mg, 9.5 
mmol) was added over 10 minutes while stirring, the mixture was then heated to 85 ºC for 5 
hours. After cooling down to room temperature it was acidified with concentrated hydrochloric 
acid to pH 1, then the solution was extracted with CH2Cl2 (3 x 10 mL). The collected organic 
phases were dried over anhydrous MgSO4, and the solvent was removed, hexanes (10 mL) 
were added to the oil and stirred for another 10 minutes. The solvent was again removed giving 
0.96 g (97% yield) of 10 as a colourless solid. 
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6.2.3. Synthesis of (±)-UB-207 and (±)-UB-207b (±)-2-((2S,3R)-2-octyl-5-
oxotetrahydrofuran-3-yl)acetic acid, (±)-2-((2S,3S)-2-octyl-5-oxotetrahydrofuran-3-
yl)acrylic acid 
The lactone 10 (0.2 g, 0.78 mmol) was dissolved in THF anhydrous (2 mL) then cooled at 0 
ºC and added to a pear-shaped flask containing LiHMDS (3.7 mL, 3.7 mmol) cooled at -78 ºC. 
The reaction mixture was stirred for 1 hour and allowed to warm to rt over 20 minutes. 2,2,2-
trifluoroethyl trifluoroacetate (0.24 mL, 1.76 mmol) was added to the flask and stirred for 1 hour. 
Saturated solution of NH4Cl (20 mL) was added and the mixture was stirred for 20 minutes, then 
concentrated HCl was added until pH 1. The solution was extracted with EtOAc (3 x 15 mL), 
dried over MgSO4 and the solvent was removed with the rotatory evaporator giving a reddish oil 
(418 mg). 
Without further purification the reddish oil was solved in toluene (20 mL), the solution was 
treated with K2CO3 (324 mg, 2.3 mmol), 18-crown-6 (52 mg, 0.2 mmol) and paraformaldehyde 
(0.98 mg, 0.03 mmol). After adding the reagents, the suspension was heated at 80 ºC for 2 
hours followed by 4 hours at 100 ºC. After cooling to down rt, saturated NH4Cl was added and 
the mixture was extracted with EtOAc (3 x 15 mL), combined organic phases were washed with 
brine and dried over MgSO4 and the solvent was removed under reduced pressure giving a 
brown oil (236 mg) that was the mixture of two regioisomers, (±)-UB-207 and (±)-UB-207b 
 
Product 10 
Colourless solid. Rf = 0.25 (hexanes/EtOAc/AcOH 8:2:0.1). 
mp = 57-58.5 ºC. 1H NMR (CDCl3, 400 MHz): δ 4.18 (ddd, J = 
7.9, 6.1, 4.5 Hz, 1H, H-6), 2.85 (dd, J = 17.7, 8.3 Hz, 1H, H-
2a), 2.70 – 2.55 (m, 2H, H-3 H-4a), 2.46 (dd, J = 15.3, 7.5 Hz, 
1H, H-4b), 2.32 (dd, J = 17.6, 7.4 Hz, 1H, H-2b), 1.74 – 1.62 
(m, 2H, CH2-1’), 1.57 – 1.37 (m, 2H, CH2-2’), 1.35 – 1.22 (m, 
10H, CH2-3’ CH2-4’ CH2-5’ CH2-6’ CH2-7’), 0.87 (t, J = 13.6 Hz, 
3H, CH3-8’). 13C NMR (CDCl3, 101 MHz): δ = 176.8 (C, C-1), 
176.1 (C, C-5), 85.0 (CH, C-6), 37.1 (CH2, C-4), 37.0 (CH, C-
3), 34.9 (CH2, C-2), 34.5 (CH2,C-1’), 31.9 (CH2, C-7’), 29.5 
(CH2, C-3’), 29.4 (CH2, C-4’), 29.3 (CH2, C-5’), 25.6 (CH2, C-
2’), 22.8 (CH2, C-6’), 14.2 (CH3, C-8’) 
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(±)-UB-207 
Rf = 0.35 (DCM/MeOH 97:3). 1H NMR (CDCl3, 400 
MHz): δ 6.32 (d, J = 2.5 Hz, 1H, H-7a), 5.70 (d, J = 2.5 
Hz, 1H, H-7b), 4.26 (dt, J = 8.5, 4.6 Hz, 1H, H-6), 3.15 – 
3.08 (m, 1H, H-3), 2.65 – 2.63 (m, 2H, CH2-2), 1.77 – 
1.60 (m, 2H, CH2-1’). 1.54 – 1.34 (m, 2H, CH2-2’), 1.33 – 
1.20 (m, 10H, CH2-3’ CH2-4’ CH2-5’ CH2-6’ CH2-7’), 0.88 
(t, J = 6.9 Hz, 3H, CH3-8’). 13C NMR (CDCl3, 101 MHz): 
δ = 176.2 (C, C-1), 169.9 (C, C-5), 138.1 (C, C-4), 123.5 
(CH2, C-7), 83.1 (CH, C-6), 40.6 (CH, C-3), 38.2 (CH2, 
C-2), 35.8 (CH2, C-1’), 31.9 (CH2, C-7’), 29.5 (CH2, C-
3’), 29.4 (CH2, C-4’), 29.3 (CH2, C-5’), 25.0 (CH2, C-2’), 
22.7 (CH3, C-6’), 14.2 (CH3, C-8’). 
  
(±)-UB-207b  
Rf = 0.35 (DCM/MeOH 97:3). 1H NMR (CDCl3, 400 
MHz): δ 6.49 (s, 1H, H-7a), 5.84 (s, 1H, H-7b), 4.46 (dt, 
J = 6.5, 6.5 Hz, 1H, H-6), 3.19 (ddd, J = 9.2, 7.1, 6.5 Hz, 
1H, H-3), 2.83 (dd,  J = 17.7, 9.2 Hz, 1H, H-4a), 2.66 
(dd, J = 17.7, 7.1 Hz, 1H, H-4b), 1.77 – 1.60 (m, 2H, 
CH2-1’), 1.54 – 1.34 (m, 2H, CH2-2’), 1.33 – 1.20 (m, 
10H, CH2-3’ CH2-4’ CH2-5’ CH2-6’ CH2-7’), 0.88 (t, J = 
6.9 Hz, 3H,CH3-8’). 13C NMR (CDCl3, 101 MHz): δ = 
176.2 (C, C-1), 170.6 (C, C-5), 138.2 (C, C-2), 129.3 
(CH2, C-7), 84.8 (CH, C-6), 43.2 (CH, C-3), 38.9 (CH2, 
C-4), 38.8 (CH2, C-1’), 31.9 (CH2, C-7’), 29.5 (CH2, C-
3’), 29.4 (CH2, C-4’), 29.3 (CH2, C-5’), 25.6 (CH2, C-2’), 
22.7 (CH3, C-6’), 14.2 (CH3, C-8’). 
6.2.4. Synthesis of (±)-methyl 2-((2S,3R)-4-methylene-2-octyl-5-oxotetrahydrofuran-3-
yl)acetate (12) and (±)-methyl 2-((2S,3S)-2-octyl-5-oxotetrahydrofuran-3-yl)acrylate (13) 
A part of the mixture of regioisomers UB-207 and UB-207b (71 mg, 0.26 mmol) previously 
obtained was dissolved in MeOH (4 mL) and TMSCl (70 µL, 0.53 mmol) was added. The 
solution was stirred for 48 hours at room temperature. The reaction was followed by TLC, when 
the starting material was consumed, the solvent was removed under reduced pressure giving a 
brown oil (69 mg) of 12 and 13. 
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                                       Product 12                                                                        Product 13 
Mixture of 12 & 13:Rf = 0.65 (DCM/MeOH) 1H NMR (CDCl3, 400 MHz): δ 6.34 (s, 0.3H, H-
16a), 6.30 (s, 0.7H, H-8a), 5.71 (s, 0.3H, H-16b), 5.65 (s, 0.7H, H-8b), 4.44 (dt, J = 6.5, 6.5 Hz, 
0.3H, H-15), 4.21 (dt, J = 6.5, 6.5 Hz, 0.7H, H-7), 3.80 (s, 0.9H, H-9), 3.71 (s, 2.1H, H-1), 3.19 
(ddd, J = 9.2, 7.1, 6.5 Hz, 0.7H, H-12), 3.15-3.08 (m, 0.7H, H-4), 2.83 (dd,  J = 17.7, 9.2 Hz, 
0.3H, H-13a), 2.66 (dd, J = 17.7, 7.1 Hz, 0.3H, H-13b), 2.60 – 2.58 (m, 1.4H, CH2-3), 1.77 – 
1.60 (m, 2H, CH2-1’ CH2-9’ ), 1.54 – 1.34 (m, 2H, CH2-2’ CH2-10’), 1.33 – 1.20 (m, 10H, CH2-3’ 
CH2-4’ CH2-5’ CH2-6’ CH2-7’ CH2-11’ CH2-12’ CH2-13’ CH2-14’ CH2-15’), 0.88 (t, J = 6.9 Hz, 
3H, CH3-8’ CH3-16’). 
6.2.5. Synthesis of (±)-2-((2S,3R)-2-octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-
3-yl)acetic acid (5) and (±)-(S)-2-((2S,3S)-2-octyl-5-oxotetrahydrofuran-3-yl)-3-
(phenylselanyl)propanoic acid (14) 
A solution of the two regioisomers (±)-UB-207 and (±)-UB-207b (165 mg, 0.61 mmols).in 
anhydrous EtOH (2 mL) was prepared under N2 atmosphere and room temperature. Another 
solution of Ph2Se2 (118 mg, 0.61 mmol) and NaBH4 (18 mg, 0.38 mmol) in anhydrous EtOH (2 
mL) under N2 and room temperature was added to the first solution. The mixture was stirred for 
3.5 hours at room temperature. Then the reaction was stopped by adding HCl (2 N) until 
reaching pH = 1. The solvent was removed by rotatory evaporation. The oil obtained was diluted 
in H2O (5 mL) and extractions were performed with DCM (3 x 8 mL). The combined organic 
phases were washed with NH4Cl 20% (2 x 5mL), saturated NaCl (2 x 5 mL) and H2O (5 mL). 
Finally, the organic phase was dried over anhydrous MgSO4, filtered and the solvent was 
removed under reduced pressure giving a brown oil which contained the mixture of both 
regioisomers which was purified by column chromatography (Hexanes/DCM 80:20) giving a 
yellow oil (20 mg). 
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Product 5 Product 14 
Mixture of 5 & 14: Rf = 0.35 (DCM/MeOH) 1H NMR (CDCl3, 400 MHz): δ 7.60 (m, 1.5H, H-18 
H-19 H-20) 7.54 (m, 3.5H, H-8 H-9 H-10), 4.44 (dt, J = 6.5, 6.5 Hz, 0.3H, H-16), 4.21 (dt, J = 
6.5, 6.5 Hz, 0.7H, H-6), 3.19 (ddd, J = 9.2, 7.1, 6.5 Hz, 0.7H, H-13), 3.15-3.08 (m, 0.7H, H-3), 
2.83 (dd,  J = 17.7, 9.2 Hz, 0.3H, H-14a), 2.66 (dd, J = 17.7, 7.1 Hz, 0.3H, H-14b), 2.60 – 
2.58 (m, 1.4H, CH2-2), 1.77 – 1.60 (m, 2H, CH2-1’ CH2-9’ ), 1.54 – 1.34 (m, 2H, CH2-2’ CH2-
10’), 1.33 – 1.20 (m, 10H, CH2-3’ CH2-4’ CH2-5’ CH2-6’ CH2-7’ CH2-11’ CH2-12’ CH2-13’ CH2-
14’ CH2-15’), 0.88 (t, J = 6.9 Hz, 3H, CH3-8’ CH3-16’). 
6.2.6. Deprotection of (±)-2-((2S,3R)-2-octyl-5-oxo-4-
((phenylselanyl)methyl)tetrahydrofuran-3-yl)acetic acid 
The selenide ether 5 (20 mg, 0.047 mmol) was dissolved in THF anhydrous (0.4 mL) then 
H2O2 35% (20 µL) were added, the reaction was stirring at room temperature for 3.5 hours. 
Then, CH2Cl2 (5 mL) and saturated NaHCO3 (2 mL) were added and the mixture was stirred for 
5 minutes. After removing the organic phase, the aqueous phase was washed with CH2Cl2 (3 x 
3 mL) and then acidified to pH = 1 with concentrated HCl. Then the extractions were done with 
CH2Cl2 (4 x 3 mL) and the combined organic phase was washed with saturated NaCl solution 
and dried over MgSO4. The solvent was removed under reduced pressure giving the product 
(±)-UB-207 (10 mg). 
(±)-UB-207 characterisation data as described previously. 
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7. CONCLUSIONS 
Although the synthetic route to (±)-UB-207 was stablished by K. Makowski in his PhD 
thesis, in this project we have achieved to separate the regioisomers obtained after the α-
methylenation. We could get rid of the undesired regiosiomer covering the methylene via a 
selenium ether, the ether formation was as easy as its latter deprotection which encourages us 
to keep studying the process to enhance its yield. 
On the other hand, it has been proved that the addition of DMAP as a catalyst on the bis-
lactone formation increased the yield remarkably (almost doubled it) without the need of 
purifying the reaction crude, thus, optimizing the synthetic route. 
Finally, after many attempts to methylate the bis-lactone (8) with different bases and 
conditions the methylation could not be achieved. In the absence of carrying out the appropriate 
tests, the bis-lactone seemed to be reacting as an electrophile, favouring the attack of the base 
to the carbonyl.  
 
Preparation of the enzymatic inhibitor UB-207. 31 
 
8. REFERENCES AND NOTES 
1. WHO European Ministerial Conference on Counteracting Obesity. European Charter on counteracting 
obesity. WHO website. 2006. 
2. NCD Risk Factor Collaboration. Articles Worldwide trends in body-mass index, underweight, 
overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement 
studies in 128.9 million children, adolescents, and adults. Lancet, 2017, 2627–2642. 
https://doi.org/10.1016/S0140-6736(17)32129-3  
3. World Health Organisation: Regional office for Europe. European Food and Nutrition Action Plan 
2015-2020. WHO website. 2015 
4. Mera, P.; Bentebibel, A.; López-Viñas, E.; Cordente, A.; Gurunathan, C.; Sebastián, D.; Vázquez, I.; 
Herrero, L.; Ariza, X.; Gómez-Puertas, P.; Asins, G.; Serra, D.; García, J.; Hegardt, F. G. C75 is 
converted to C75-CoA in the hypothalamus, where it inhibits carnitine palmitoyltransferase 1 and 
decreases food intake and body weight. Biochem. Pharmacol., 2009, 77, 1084–1095. 
https://doi.org/10.1016/j.bcp.2008.11.020  
5. Kuhajda, F. P.; Pizer, E. S.; Li, J. N.; Mani, N. S.; Frehywot, G. L.; Townsend, C. A. Synthesis and 
antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA, 2000, 97:3450–4. 
https://doi.org/10.1073/pnas.050582897  
6. National Center for Biotechnology Information, U.S. National Library of Medicine. 
https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=2194 
(accessed Dec 17, 2017) 
7. Obici, S.; Feng, Z.; Arduini, A.; Conti, R.; Rossetti, L. Inhibition of hypothalamic carnitine 
palmitoyltransferase-1 decreases food intake and glucose production. Nat Med., 2003, 9:756–61. 
https://doi.org/10.1038/nm873  
8. Makowski, K.; Mir, J. F.; Mera, P.; Ariza, X.; Asins, G.; Hegardt, F. G.; Herrero, L.; García, J.; Serra, D. 
European Journal of Medicinal Chemistry (±) -UB006: A new fatty acid synthase inhibitor and 
cytotoxic agent without anorexic side effects. Eur. J. Med., Chem., 2017, 131, 207–221. 
https://doi.org/10.1016/j.ejmech.2017.03.012  
9. Ceccarelli, S. M.; Chomienne, O.; Gubler, M., Arduini, A. Carnitine Palmitoyltransferase (CPT) 
Modulators: A Medicinal Chemistry Perspective on 35 Years of Research. J. Med. Chem., 2011, 54 
(9), 3109–3152 https://doi.org/10.1021/jm100809g  
10. Makowski, K, Facultat de química i Facultat de Farmàcia, Departament de Química Orgànica, 
Universitat de Barcelona. Tesi doctoral, 2012. 
11. Fritz, I. B.; Yue, K. T. N. Long-chain carnitine acyltransferase and the role of acylcarnitine derivatives 
in the catalytic increase of fatty acid oxidation induced by carnitine. J. Lipid Res., 1963, 4, 279–288.  
12. McGarry, J. D.; Woeltje, K. F.; Kuwajima, M.; Foster, D. W. Regulation of ketogenesis and the 
renaissance of carnitine palmitoyltransferase. Diabetes/metabolism research and reviews, 1989, 5, 
271–284. https://doi.org/10.1002/dmr.5610050305  
13. Parker, L. Total Synthesis of dl-Avenaciolide. J. Org. Chem., 1973. 2431(4). 
https://doi.org/10.1021/jo00954a015  
14. Riofski, M. V.; John, J. P.; Zheng, M. M.; Kirshner, J.; Colby, D. A. Exploiting the Facile Release of 
Trifluoroacetate for the r -Methylenation of the Sterically Hindered Carbonyl Groups on Sclareolide 
and Eburnamonine. J. Org. Chem., 2011, 3676–3683. https://doi.org/10.1021/jo102114f  
32 Galindo Muñoz, Alex 
 
15. Lawson, A. The decarboxylative acylation of succinic acid derivatives. Part II o-
Hydroxyphenylsuccinic, tricarballylic, and thiobenzamidosuccinic acid. J. Chem. Soc. 1957, 0, 144-150 
https://doi.org/10.1039/JR9570000144  
16. Danheiser, R.; Miller, R.; Brisbois, R. G.; Park, S. Z. An Improved Method for the Synthesis of α-Diazo 
Ketones. J. Org. Chem., 1990, 55, 1959–1964. https://doi.org/10.1021/jo00293a053 
17. Li, J., Sha, Y. A Convenient Synthesis of Amino Acid Methyl Esters. Molecules, 2008, 1111–1119. 
https://doi.org/10.3390/molecules13051111 
 
Preparation of the enzymatic inhibitor UB-207. 33 
 
12. ACRONYMS 
ACS: acetyl-CoA synthetase 
ATP: adenosine triphosphate 
CACT: carnitine acylcarnitine translo-
case 
CPT 1: carnitine palmitoyltransferase 1 
CPT 2: carnitine palmitoyltransferase 2 
DCM: dichloromethane 
DMAP: 4-dimethylaminopyridine 
EtOAc: ethyl acetate 
EtOH: ethanol 
FA: fatty acid 
FAO: fatty acid oxidation 
FAS: fatty acid synthase 
LCFA: long chain fatty acid 
LDA: lithium diisopropylamide 
LiHMDS: lithium 
bis(trimethylsilyl)amide 
MeOH: methanol 
NMR: nuclear magnetic resonance 
Rf: retention factor 
tBuLi: tert-butyllithium 
THF: tetrahydrofuran 
TLC: thin layer chromatography 
TMSCl: trimethylsilyl chloride 
TMS: tetramethylsilane 
Mp: melting point 
 
  
